
The chief executive of Medicines Australia has called for a strengthening of Australia’s intellectual property system in order to restore the country’s place as a global biotech and pharma leader.
Speaking at a Parliamentary Friends of Medicines event, Tim James called on the Australian government to rethink its IP framework. He said: “IP is at the heart of innovation, and protecting it is critical for future economic growth in Australia. For a modern, knowledge-based economy like Australia’s, IP is a particularly valuable commodity, currently worth an estimated A$250 billion ($213 billion) to the economy, or nearly a fifth of the nation’s GDP.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze